Table 1 The baseline characteristics of eligible studies
First Author, Year (reference) | Country | Center | Inclusion year(s) | Elderly definition (year-old), [special population] | Overall N (MACE/MACCE rate, %) | Male (%), Mean age (years) | CAD (%) | Primary/ Emergent PCI (%) | MACE/MACCE components | Median/ Reported follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|
Cheng, 2023 [15] | China | SC | 2009–2011 | ≥ 60 | 791 (17.32) | NR | NR | NR | ACM, MI, Revasc, Stroke | 34 |
Li, 2023 [16] | China | SC | 2019–2023 | ≥ 65 | 1286 (8.8) | 61.35, 73.5 | NSTE-ACS: 47.2 STEMI: 41.7 | 41.7 | ACM, CM, MI, Stroke, TVR | 1 |
Marschall, 2023 [17] | Spain | MC | 2012–2019 | ≥ 75 | 2725 (9.9) | 65.65, 80.97 | ACS: 65 | NR | CM, MI, Stroke, Revasc | 12 |
Park, 2023 [18] | South Korea | MC | 2017–2021 | ≥ 75 | 650 (7.8) | 56.3, 80.5 | NSTE-ACS: 54.8 SA: 45.2 | None | ACM, MI, TVR, Stroke, Stent Thrombosis | 12 |
Shimono, 2023 [19] | Japan | SC | 2017–2020 | ≥ 65 | 239 (19.2) | 73.6, 74.87 | Stable CAD: 100 | None | ACM, MI, Stroke, HFRH | 32.1 |
Yan, 2023 [20] | China | SC | 2013 | ≥ 65 | 2131 (12) | 63.2, 70.3 | ACS: 60.6 | NR | ACM, MI, Stroke | 120 |
Fallahzadeh, 2022 [21] | Iran | SC | 2015–2019 | ≥ 80 | 610 (20.3) | 65.7, 84 | NSTE-ACS: 47.5 STEMI: 52.5 | NR | ACM, ACS, Stroke/ TIA, Revasc | 12 |
Horikoshi, 2022 [22] | Japan | MC | 2008–2018 | ≥ 75 | 932 (18.9) | 67.5, 81 | ACS: 58 | NR | ACM, MI | 25 |
Lang, 2022 [23] | China | SC | 2014–2019 | ≥ 65 | 617 (33.9) | 60.3, 73 | STEMI: 100 | 100 | ACM, MI, Stroke, Revasc | 56 |
Marino, 2022 [24] | Italy | SC | 2009–2020 | ≥ 85 | 166 (41) | 43.4, 87.8 | NSTE-ACS: 60.8 STEMI: 39.2 | NR | CM, MI, Revasc, Hosp. | 18.5 |
Otowa, 2022 [25] | Japan | MC | 2017 | ≥ 90 | 872 (8.1) | 46.4, 92 | NSTE-ACS: 25.8 STEMI: 40.7 SA: 17 | NR | CM, MI, Stroke | 12 |
Wang, 2022 [26] | China | SC | 2009–2010 | ≥ 65 | 437 (16.2) | 80.3, 72 | STEMI: 100 | 100 | ACM, MI, Revasc | 59 |
Wang, 2022 [27] | China | SC | 2013–2020 | ≥ 80 | 604 (19.5) | 53.1, 82 | NSTE-ACS: 67.4 STEMI: 32.6 | 20.5 | CM, MI, Stroke, HFRH | 48 |
Lattuca, 2021 [28] | France | MC | 2012–2015 | ≥ 75 [BARC 2, 3, or 5] | 181 (16.6) | 56.4, 81.6 | NSTE-ACS: 68 STEMI: 32 | 32.6 | CM, MI, Stroke | 12 |
Lim, 2021 [29] | Australia | MC | 2013–2017 | ≥ 80 | 1875 (8) | 59.3, 84.2 | NSTE-ACS: 100 | NR | ACM, MI, Stroke, Major bleeding, TVR/TLR, in-hospital cardiogenic shock or stent thrombosis, and a new requirement for dialysis. | 1 |
Kalyoncuoğlu, 2021 [30] | Turkey | SC | 2017–2019 | ≥ 60 | 253 (19) | 71.5, 68.5 | NSTEMI: 100 | NR | ACM, MI, Stroke, Revasc | 12 |
Kanwar, 2021 [31] | USA | MC | 2005–2008 | ≥ 65 | 629 (NR) | 69, 74.8 | NR | NR | ACM, MI | 35 |
Maruyama, 2021 [32] | Japan | MC | 2012–2013 | ≥ 75 | 597 (10.2) | 65.7, 80.9 | ACS: 40.9 SA: 59.1 | NR | ACM, MI, Stroke | 51.6 |
Morici, 2020 [33] | Italy | MC | 2012–2017 | ≥ 75 | 630 (10.8) | 62.9, 80.2 | ACS: 100 | NR | ACM, MI, Stroke | 12 |
Zhang, 2020 [34] | China | SC | 2015–2019 | ≥ 70, [T2DM] | 273 (17.2) | 44.3, 78.4 | ACS: 100 | NR | CM, MI, Revasc | 12 |
Berezhnoi, 2019 [35] | Russia | SC | 2014–2017 | ≥ 80 [MVD] | 305 (21.6) | 34.4, 84.2 | NSTE-ACS: 74.4 STEMI: 25.6 | NR | ACM, MI, Stroke | 12 |
Huang, 2019 [36] | China | SC | 2015–2017 | ≥ 65 | 711 (NR) | 66.9 | NSTEMI: 43 STEMI: 57 | NR | Cardiovascular/ cerebrovascular accident | 24.6 |
Aghajani, 2018 [37] | Iran | SC | 2004–2013 | ≥ 65 | 2772 (14.1) | 62.3, 70.8 | NSTE-ACS: 50 STEMI: 24.1 | None | CM, MI, CABG Revasc, UA hosp., TVR/TLR | 60 |
de la Torre Hernandez, 2018 [38] | Spain | MC | 2006–2013 | ≥ 75, [MVD] | 1830 (NR) | 62.1, 81.1 | STEMI: 100 | 100 | CM, MI | 24 |
De Rosa, 2018 [39] | Italy | MC | NR | ≥ 75 | 311 (3.9) | 66.6, 81.5 | NSTE-ACS: 100 | NR | CM, MI, Stent Thrombosis | 12 |
Gerber, 2017 [40] | UK | SC | 2006–2011 | ≥ 75 | 580 (14.1) | 57.4, 79.8 | ACS: 58.3 SA: 41.7 | 16.2 | CM, MI, Stroke, TVR, TLR | 30.8 |
Wei, 2016 [41] | China | SC | 2012–2013 | ≥ 60 [LMCA] | 64 (17.2) | 75, 73.9 | STEMI: 9.4 | NR | CM, MI, Angina, Stroke, Worsening of HF, TVR | 15.2 |
Yu, 2016 [42] | China | SC | 2008–2012 | ≥ 60 | 1090 (8) | 62.4, 68.9 | NSTE-ACS: 100 | NR | CM, MI | 36 |
Uthamalingam, 2015 [43] | USA | SC | 2000–2008 | ≥ 80 | 320 (5) | 50.9, 83.6 | ACS: 76.6 SA: 16.25 | NR | CM, MI, TVR | 12 |
Liu, 2013 [44] | Japan | SC | 2005–2009 | ≥ 65 [CTO] | 153 (18.3) | 60.8, 76 | NR | NR | CM, MI, TLR | 36 |
Chen, 2012 [45] | China | SC | 2005–2010 | ≥ 75 [multi-lesion] | 502 (15.3) | 63.5, 78.5 | NSTE-ACS: 79.1 STEMI: 17.5 | NR | CM, MI, Stroke, TLR/TVR | 35.7 |
López-Palop, 2009 [46] | Spain | SC | 2002–2006 | ≥ 80 | 176 (32.4) | 60.8, 82.8 | MI: 38.6 SA: 8.0 | NR | ACM, MI, Revasc | 26.3 |
Ma, 2008 [47] | China | SC | 2004–2006 | ≥ 85 | 80 (16.25) | 53.75, 87.5 | NSTE-ACS: 81.25 STEMI: 18.75 | 18.75 | CM, MI, TLR, TVR | 36 |
Gach, 2003 [48] | Belgium | SC | 1994–1999 | ≥ 80 | 158 (NR) | 54.4, 85.2 | UA: 49.4 MI: 5 | 76 | ACM, MI, Revasc | 24 |